Related Experiment Video

Updated: Jun 15, 2026

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

D3 receptor target engagement in humans with ABT-925 using [11C](+)-PHNO PET

Mark Day1, Earle Bain, Gerard Marek

  • 1Global Pharmaceutical Research and Development, Translational Neuroimaging, Abbott, Abbott Park, IL60064, USA. mark.day@abbott.com

The International Journal of Neuropsychopharmacology
|March 4, 2010
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

Determining Binding Affinity (KD) of Radiolabeled Antibodies to Immobilized Antigens07:39

Determining Binding Affinity (KD) of Radiolabeled Antibodies to Immobilized Antigens

Published on: June 23, 2022

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...